Summit's ridinilazole beats vancomycin in C. diff study

|About: Summit Therapeutics (SMMT)|By:, SA News Editor

Results from a Phase 2 clinical trial, CoDIFy, evaluating Summit Therapeutics' (SMMT -0.7%) now-lead candidate ridinilazole for the prevention of recurrence of infection from Clostridium difficile (C. diff), showed a substantial treatment advantage versus vancomycin. The results were just published in PLOS ONE.

Treatment with ridinilazole, an orally available small molecule antibiotic, resulted in a 59% reduction in recurrence versus vancomycin (14.3% vs. 34.8%).

Phase 3 development should commence next year.

Previously: Summit's ridinilazole beats vancomycin in mid-stage C. diff study (Nov. 23, 2015)

Subscribe for full text news in your inbox